期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.766200
关键词
natural killer; T cell lymphoma; anlotinib; anti-PD-1 antibody; pegaspargase; radiotherapy
类别
资金
- National Science and Technology Major Project [2018ZX09734003]
- National Natural Science Foundation of China [81872902, 82073917, 82103579, 82104273]
- Youth Funds of the Basic and Applied Basic Research Foundation of Guangdong Province [2020A1515110089]
- Sun Yat-Sen University Cancer Center Clinical Research 308 Program [2014-fxy-106, 2016-fxy-079]
This study evaluated the efficacy and safety of a combined regimen of anti-PD-1 antibody, anlotinib, and pegaspargase sandwiched with radiotherapy in localized NKTL. The results showed a high overall response rate and complete response rate, indicating the promising effectiveness and tolerability of this treatment approach.
Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse events (TRAEs). Herein we retrospectively evaluated the efficacy and safety of the combined regimen of anti-PD-1 antibody, anlotinib and pegaspargase sandwich with radiotherapy in localized NKTL. Anti-PD-1 antibody and pegaspargase at 2500 U/m(2) were administered on day 1, while anlotinib (12 mg once a day) was orally administered on days 1-14. The treatment was repeated every 3 weeks. All the eight patients included received 3 cycles of the regimen followed by radiotherapy and an additional 3 cycles. The overall response rate was 100%, and the complete response rate was 87.5%. With a median follow-up time of 35.5 months (range, 34.03-40.90 months), median PFS and OS times were not reached. The 3-year PFS and OS rates were 100% and 100%, respectively. All patients were alive at the last follow-up. No treatment-related death and no grade 4 TRAE was reported. No grade 3/4 hematological toxicity was detected, and half of the patients didn't report any hematological toxicity. This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据